mybacs
Sebastian Wahl has a diverse work experience in various roles and industries. In 2013, they worked at WILEX AG, and in 2012, they were employed at RLP AgroScience GMBH. In 2016, Sebastian had roles at both The Boston Consulting Group and FogPharma. Sebastian also worked at Strategy&, part of the PwC network in 2017. In 2018, they joined EQT Life Sciences, formerly known as LSP. In 2019, Sebastian founded their own company called mybacs GmbH, where they served as the Founder & CEO. Most recently, in 2021, they became a Partner at Generations Fund.
Sebastian Wahl attended St Leonards School until 2012. Sebastian then went on to pursue a Bachelor of Science (B.Sc.) in Pharmaceutical Sciences at ETH Zürich from 2012 to 2015. Subsequently, Sebastian completed a Master of Science (M.Sc.) in Medicinal & Industrial Pharmaceutical Sciences at ETH Zürich from 2015 to 2017.
mybacs
mybacs is a DTC, research-driven, Biotechnology company specialized in the human microbiome. Our goal is to revolutionize the market around intestinal healthcare and thus make a decisive contribution to the daily well-being of our customers. Our team of pharmaceutical scientists and physicians is focused on the development of innovative andhighly-dosed synbiotic supplements. These are aligned by our singular formulations from specifically selected probiotic cultures, prebiotics as well as minerals and vitamins tailored to the individual needs of our customers.